CLINICAL REVIEW / PEER REVIEWED

Pharmacologic Treatments for Idiopathic Pulmonary Fibrosis

Author and Disclosure Information

 

References

DIAGNOSIS

IPF belongs in the general class of idiopathic interstitial pneumonias (IIPs), which are characterized by varying degrees of inflammation and fibrosis of lung interstitium.4 All subtypes of IIPs cause dyspnea and diffuse abnormalities on HRCT, and all vary from each other histologically. Table 1 outlines the key features of each.5-8

Key Characteristics of Idiopathic Interstitial Pneumonias image

Because of its vague symptomology and the extensive workup needed to rule out other diseases, patients with IPF often have symptoms for one to two years before a diagnosis is made.1 Physical exam may reveal fine inspiratory rales in both lung bases and digital clubbing; eventual signs of pulmonary hypertension and right-sided heart failure may be appreciated.1,9

There are no specific diagnostic laboratory tests to confirm IPF; however, baseline labwork (as outlined in the case presentation) is typically ordered to rule out infection, thyroid disease, or connective tissue disease.10 Many patients are referred to a cardiologist before being seen by a pulmonologist; cardiac stress testing may be done, and an echocardiogram may be performed to rule out heart failure.

Diagnostic testing may include pulmonary function testing, HRCT of the chest, and lung biopsy.10 Tissue samples from patients with IPF reveal different stages of disease, including dense fibrosis with honeycombing, subpleural or paraseptal distribution, fibroblast foci, and normal tissue.11 Pulmonary function test results will show a restrictive pattern. Both forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) will be reduced, and the FEV1/FVC ratio preserved. Due to decreased functional lung volume, diffusing capacity of the lung for carbon monoxide (DLCO) will also be reduced.4,12

The honeycombing of lung tissue in idiopathic pulmonary fibrosis image

The differential is broad and includes allergic asthma, bronchitis, COPD, lung cancer, hypersensitivity pneumonitis, asbestosis, or pulmonary embolism.

Continue to: TREATMENT HISTORY

Pages

Recommended Reading

U.S. influenza activity widespread to start 2018
Clinician Reviews
Abstract: Antibiotic Prescribing for Nonbacterial Acute Upper Respiratory Infections in Elderly Persons
Clinician Reviews
Abstract: Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated With Different Outcomes Among Patients With Venous Thromboembolism?
Clinician Reviews
House cleaning linked to lung function decline
Clinician Reviews
Climate change is worsening allergies, expert says
Clinician Reviews
New approaches needed for food allergies in minority children
Clinician Reviews
TB in 2017: Good news and bad news
Clinician Reviews
EAGLES: Smoking cessation therapy did not up cardiovascular risk
Clinician Reviews
Caffeine for apnea of prematurity found safe, effective at 11 years
Clinician Reviews
CDC: Marijuana use may spur industries to rethink current policies
Clinician Reviews